Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Agnese Cangini
Observed names:
A Cangini,
A. Cangini
Institutions:
Università Cattolica del Sacro Cuore,
Italian Medicines Agency
Observed institutions:
Università Cattolica del Sacro Cuore,
Italian Medicines Agency
ORCID:
0000-0002-1640-3993
Observed ORCID:
0000-0002-1640-3993
OpenAlex ID:
A5067964466
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency
2019
·
Federico Villa
, Michaela Tutone
, et al.
·
Health Policy
·
57
Monitoring the community use of antibiotics in Italy within the National Action Plan on antimicrobial resistance
2020
·
Agnese Cangini
, Filomena Fortinguerra
, et al.
·
British Journal of Clinical Pharmacology
·
43
PDF
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines
2020
·
Jane Moseley
, Spiros Vamvakas
, et al.
·
British Journal of Clinical Pharmacology
·
38
PDF
Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective
2022
·
Salvatore Crisafulli
, Elisabetta Poluzzi
, et al.
·
Frontiers in Drug Safety and Regulation
·
30
PDF
Hospital Antibiotic Use during COVID-19 Pandemic in Italy
2023
·
Alessandro Perrella
, Filomena Fortinguerra
, et al.
·
Antibiotics
·
29
PDF
Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy
2023
·
Francesco Trotta
, Maria Alessandra Guerrizio
, et al.
·
JAMA Health Forum
·
23
PDF
Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014–2019
2022
·
Federico Villa
, Aurora Di Filippo
, et al.
·
Frontiers in Medicine
·
19
PDF
Variables affecting pricing of orphan drugs: the Italian case
2021
·
Claudio Jommi
, Elisabetta Listorti
, et al.
·
Orphanet Journal of Rare Diseases
·
18
PDF
Standardized Reporting for Rapid Relative Effectiveness Assessments of Pharmaceuticals
2014
·
Sarah Kleijnen
, Iris Pasternack
, et al.
·
International Journal of Technology Assessment in Health Care
·
15
Evidence Requirements for Reimbursement of Pharmaceuticals Across Europe
2015
·
Oyinlola Oyebode
, Zoe Garrett
, et al.
·
International Journal of Technology Assessment in Health Care
·
13
Impact of COVID-19 pandemic on medication use in the older Italian population
2022
·
Alessandra Marengoni
, Agnese Cangini
, et al.
·
Aging Clinical and Experimental Research
·
12
PDF
Patterns of community antibiotic use with reference to the AWaRe classification of the World Health Organization
2024
·
Carlo Gagliotti
, Agnese Cangini
, et al.
·
JAC-Antimicrobial Resistance
·
10
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
2025
·
Valentina Giunchi
, Michele Fusaroli
, et al.
·
British Journal of Clinical Pharmacology
·
9
Medication use in Italian nursing homes: preliminary results from the national monitoring system
2023
·
S. Zito
, E. Poluzzi
, et al.
·
Frontiers in Pharmacology
·
8
PDF
Medication Use and Costs Among Older Adults Aged 90 Years and Older in Italy
2022
·
Maria Beatrice Zazzara
, Agnese Cangini
, et al.
·
Frontiers in Pharmacology
·
8
PDF
L’uso degli antibiotici in Italia. Il rapporto nazionale OsMed 2019
2021
·
Filomena Fortinguerra
, Fabio Ambrosino
, et al.
·
Recenti Progressi in Medicina
·
8
PDF
How medicines are used in Italy: Data from the National Report 2018
2019
·
Agnese Cangini
, Federico Villa
, et al.
·
Health Policy and Technology
·
6
The Nationwide Osmed Health-Db Database. A Tool To Support Healthcare Decision-Making And Real-World Evidence Generation
2015
·
L Degli Esposti
, S Saragoni
, et al.
·
Value in Health
·
5
PDF
L’uso dei farmaci in Italia. Il Rapporto Nazionale OsMed 2020
2021
·
Simona Zito
, Filomena Fortinguerra
, et al.
·
Recenti Progressi in Medicina
·
4
PDF
Savings From Biosimilars Use in the Italian National Health Service
2025
·
Maria Lucia Marino
, Benedetta Bellini
, et al.
·
Value in Health Regional Issues
·
3
PDF
Access and use of WHO essential medicines in Italy
2023
·
Alessandro Petrella
, Filomena Fortinguerra
, et al.
·
Frontiers in Public Health
·
3
PDF
Terapia dell’emofilia A: spesa e consumo per l’anno 2022 e scenari di spesa futura
2023
·
Giuseppe Marano
, Roberto Da Cas
, et al.
·
Recenti Progressi in Medicina
·
3
Farmaci biosimilari: i rapporti OsMed sul monitoraggio dei consumi e della spesa in Italia
2021
·
Simona Zito
, Rebecca De Fiore
, et al.
·
Recenti Progressi in Medicina
·
3
PDF
Quanto vale la negoziazione del prezzo di un nuovo farmaco in Italia?
2020
·
Federico Villa
, Claudio Jommi
, et al.
·
Recenti Progressi in Medicina
·
3
Generic and biosilimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA)
2015
·
Alessandro Monaco
, Federica Mammarella
, et al.
·
Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
·
3
Show more works
View as search
Works count:
39
Citation count:
388
H-index:
11
I10-index:
12
Year
Topic
Type